drugset

drugset / Trial / NCT04036019

A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

NCT04036019 ↗

Phase 1 Completed 13 enrolled Shanghai Tongji Hospital, Tongji University School of Medicine Shanghai AbelZeta Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, non-randomized clinical study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r B cell lymphoma who received CD19 CAR-T therapy.

Timeline

Start: 2019-08-20
Primary completion: 2022-06-20
Completion: 2022-06-20

Publications

Li P, Liu W, Zhou L, Ye S, Zhu D, Huang J, Li J, Zheng C, Zhu S, Yao X, Zhu K, Yao Y, Qiu L, Liang A, Zou D. C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: A phase I clinical study. Am J Hematol. 2024 Dec;99(12):2306-2312. doi: 10.1002/ajh.27488. Epub 2024 Oct 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	C-CAR066	Cell therapy	2e+06 cells/kg	Intravenous
Subject	C-CAR066	Cell therapy	3e+06 cells/kg	Intravenous

Indications